Global Partners LP-Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

Prnewswire·2025-09-17 21:00

For the primary endpoint,Â orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs. ...